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shown in Table 3 is also very similar despite the above-men-
tioned differences in the proportion of patients treated in a lobar
fashion.
In summary, we totally agree with Garin et al. that better
dosimetry models for therapeutic planning will be welcomed
and their development is warranted, but we respectfully disagree
that they are crucial, since the currently used methods result in
signiﬁcant clinical activity with an acceptable incidence of liver
toxicity. Most importantly, we cannot ﬁnd any scientiﬁc basis
to sustain that glass microspheres have substantial beneﬁts over
resin microspheres or vice versa. What the available evidence
shows is that radioembolization is indeed a very consistent
therapeutic procedure irrespective of the device used and the
type of tumor treated, and that future efforts should be dedicated
to improve their performance and to ﬁnd the precise role it may
play in the evolving treatment paradigm of primary and second-
ary liver tumors.
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manuscript.To the Editor:
Onepaperwith impressiveﬁndings recently published in The Jour-
nal of Hepatology by Veldhuijzen et al., reported that on-site testing
could increase thedetecting rateofhepatitisB forhigh-riskpersons
[1].Wewould like to comment that Veldhuijzen et al.’s paper high-
lights the concept that only thosewho know they are infectedwith
hepatitis B could have the chance to receive antiviral treatment.
Likewise, Hsu et al.’s study showed that using electronic health
records among primary care providers could signiﬁcantly increase
the screening rate of hepatitis B for high-risk persons [2]. Li et al.
reported that those having a family physician and having better
knowledge of hepatitis B could be associated with increased
screening rates of hepatitis B [3]. These studies provide valuable
evidence that hepatitis B screening recommended by primary care
providers could increase the detecting rate of hepatitis B.
Taiwan is the ﬁrst country in the world to a commence
national hepatitis B immunization program for newborns.Journal of Hepatology 20Initially, hepatitis B vaccine was only given to newborns whose
mothers were hepatitis B carriers since July 1984. Two years
later, universal immunization has been extended to all newborns
from 1986 to date [4]. Since the prevalence of hepatitis B carriers
was around 14.7–19.5% in Taiwan before universal immunization
[5,6], and the current CDC guidelines already recommend screen-
ing of all subjects born in countries with hepatitis B prevalence
P2% [7], based on cost-beneﬁt effect, we would like to suggest
that migrants who were born in Taiwan before 1986 should be
recommended for hepatitis B screening.13 vol. 58 j 1053–1061 1057
Shih-Wei Lai
Editor
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Reply to: ‘‘Identiﬁcation of chronic hepatitis B’’
To the Editor:
We appreciate the letter to the editor regarding our paper on the
results of a project offering on-site hepatitis B testing to Chinese
migrants in Rotterdam [1]. To take Lai and Liao’s suggestion to
screen persons born in Taiwan before 1986 further, we would like
to recommend offering screening to all persons born in hepatitis
B endemic countries before the introduction of universal
vaccination.
Additionally, Lai and Liao rightly observe that primary care
providers could play an important role in the detection of chronic
hepatitis B infections. To achieve a substantial increase in the
number of identiﬁed patients with chronic hepatitis B, we feel
efforts should be targeted at several healthcare settings. Hwang
et al. studied ten thousand patients receiving chemotherapy
and found that only 17% were screened for hepatitis B [2]. This
shows that besides improving screening rates through outreach
programmes and interventions aimed at primary care, room for
improvement also exists in the hospital setting.
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